BioVersys AG (CH:BIOV)
:BIOV
Best Available Therapy, Bv100 With 50 Mg Polymyxin B Plus Ceftazidime/Avibactam, Bv100 With 50 Mg Polymyxin B Plus Cefiderocol
Hospital Acquired Bacterial Pneumonia (Habp), Ventilator Associated Bacterial Pneumonia (Vabp), Blood Stream Infection, Meningitis, Bacterial, Ventriculitis, Infectious
Phase II
Not Yet Recruiting
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Feb 17, 2026
Hrze, Hrze Plus Alpe375, Hrze Plus Alpe500, Hrze Plus Alpe625
Tuberculosis Meningitis
Phase II
Not Yet Recruiting
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
Jan 16, 2026
―
Bv100, Polymyxin B, Colistin, Ampicillin-Sulbactam, Meropenem 2 Grams Tid
Hospital Acquired Bacterial Pneumonia (Habp), Ventilator Associated Bacterial Pneumonia (Vabp), Colistin Resistanrt Abc, Acinetobacter Baumannii-Calcoaceticus Complex
Phase III
Not Yet Recruiting
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Jan 07, 2026
Itraconazole 200 Mg, Bv100
Bacterial Infections
Phase I
Completed
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
Jan 05, 2023
―
Bv100
Bacterial Infections
Phase I
Completed
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
Jan 05, 2023
―
Bat, Bv100 Plus Polymyxin B
Ventilator Associated Pneumonia
Phase II
Completed
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
Jan 04, 2023
―
Bv100
Healthy Participants
Phase I
Completed
A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment
Sep 08, 2022
―
Midazolam, Bv100
Healthy Volunteers
Phase I
Completed
A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
Sep 07, 2022
―
Bv100
Renal Impairment
Phase I
Completed
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Oct 08, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BioVersys AG (BIOV) have in its pipeline
BIOV is currently developing the following drugs: Best Available Therapy, Bv100 With 50 Mg Polymyxin B Plus Ceftazidime/Avibactam, Bv100 With 50 Mg Polymyxin B Plus Cefiderocol, Hrze, Hrze Plus Alpe375, Hrze Plus Alpe500, Hrze Plus Alpe625, Bv100, Polymyxin B, Colistin, Ampicillin-Sulbactam, Meropenem 2 Grams Tid. These drug candidates are in various stages of clinical development as the company works toward FDA approval.